• Total comprehensive income for shareholders A$166 million
• A$222 million cash and short-term investments at 31 December 2024
• A$56 million US royalty income from DAYBUE™ (trofinetide) in 2024, up 110%

Neuren Pharmaceuticals reported a record total comprehensive income of A$166 million for 2024, comprising A$142 million profit after tax and A$24 million foreign currency translation gain. The company's revenue from the successful development and commercialisation of DAYBUE™ (trofinetide) reached A$445 million across 2023 and 2024. In 2024, Neuren earned A$56 million in US royalty income from DAYBUE™, up 110% from A$27 million in 2023. Acadia has provided guidance for DAYBUE™ full-year US net sales in 2025 of US$380-405 million, which is expected to translate to royalties of A$62-67 million for Neuren. DAYBUE™ was also approved in Canada, with first sales expected in Q3 2025. Neuren's second drug candidate, NNZ-2591, has shown positive results in Phase 2 trials for Phelan-McDermid, Pitt Hopkins and Angelman syndromes, with preparations underway for a planned Phase 3 trial in Phelan-McDermid syndrome in mid-2025. The company has a strong cash position of A$222 million at the end of 2024, which increases to A$359 million on a pro-forma basis after accounting for the receipt of the PRV sale proceeds, sales milestone and Q4 2024 royalty, and the payment of Q4 2024 tax.

Acadia has provided guidance for DAYBUE™ full-year US net sales in 2025 of US$380-405 million. Assuming this guidance is met and an exchange rate of 0.65, Neuren anticipates earning US royalties of A$62-67 million.